Evidence map›Paper›PMID 27342991›Full record

ReviewWorld journal of urology2017

Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.

M N Pham, A B Apolo, M De Santis, M D Galsky, B C Leibovich, L L Pisters, A O Siefker-Radtke, G Sonpavde, G D Steinberg, C N Sternberg and 4 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 11 institutions in 3 countries.

M N PhamUniversity of North Carolina School of Medicine, Chapel Hill, NC, USA.
A B ApoloNational Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
M De SantisCancer Research Unit, University of Warwick, Coventry, UK.
M D GalskyThe Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
B C LeibovichDepartment of Urology, Mayo Clinic, Rochester, MN, USA.
L L PistersUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
A O Siefker-RadtkeUniversity of Texas MD Anderson Cancer Center, Houston, TX, USA.
G SonpavdeUniversity of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL, USA.
G D SteinbergSection of Urology, Department of Surgery, The University of Chicago Medical Center, Chicago, IL, USA.
C N SternbergSan Camillo and Forlanini Hospitals, Rome, Italy.
S T TagawaWeill Cornell Medicine, New York, NY, USA.
A Z WeizerDivision of Urologic Oncology, Department of Urology, University of Michigan, Ann Arbor, MI, USA.
M E WoodsDepartment of Urology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
M I MilowskyDivision of Hematology/Oncology, Department of Medicine, University of North Carolina Lineberger Comprehensive Cancer Center, 3rd Floor Physician's Office Building, 170 Manning Drive, Chapel Hill, NC, 27599, USA. matt_milowsky@med.unc.edu.
University of North Carolina at Chapel Hill · USThe University of Texas MD Anderson Cancer Center · USCarlo Forlanini Hospital · ITCornell University · USIcahn School of Medicine at Mount Sinai · USMayo Clinic in Arizona · USNational Cancer Institute · USUniversity of Alabama at Birmingham · USUniversity of Chicago Medical Center · USUniversity of Michigan–Ann Arbor · USUniversity of Warwick · GB

Funding

Bladder Cancer ProgramZIABC011351 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI APOLO, ANDREA · 2010 to 2025
$9.4M
Intramural NIH HHS ZIA BC011351
6 · The paper itself

Abstract

purposeTo review the management of metastatic upper tract urothelial carcinoma (UTUC) including recent advances in targeted and immune therapies as an update to the 2014 joint international consultation on UTUC, co-sponsored by the Société Internationale d'Urologie and International Consultation on Urological Diseases.

methodsA PubMed database search was performed between January 2013 and May 2016 related to the treatment of metastatic UTUC, and 54 studies were selected for inclusion.

resultsThe management of patients with metastatic UTUC is primarily an extrapolation from evidence guiding the management of metastatic urothelial carcinoma of the bladder. The first-line therapy for metastatic UTUC is platinum-based combination chemotherapy. Standard second-line therapies are limited and ineffective. Patients with UTUC who progress following platinum-based chemotherapy are encouraged to participate in clinical trials. Recent advances in genomic profiling present exciting opportunities to guide the use of targeted therapy. Immunotherapy with checkpoint inhibitors has demonstrated extremely promising results. Retrospective studies provide support for post-chemotherapy surgery in appropriately selected patients.

conclusionsThe management of metastatic UTUC requires a multi-disciplinary approach. New insights from genomic profiling using targeted therapies, novel immunotherapies, and surgery represent promising avenues for further therapeutic exploration.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarboplatinCarcinoma, Transitional CellCisplatinDeoxycytidineDocetaxelGemcitabineHumansImmunotherapyIndolesKidney NeoplasmsKidney PelvisAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsatezolizumabavelumabBevacizumabCarboplatinCisplatinDeoxycytidineDocetaxelGemcitabineIndolesNiacinamidePaclitaxelpembrolizumabPhenylurea CompoundsPyrrolesSorafenibSunitinibTaxoidsAnti-PD-1Anti-PD-L1ChemotherapyImmune checkpoint inhibitorsImmunotherapyTargeted therapyUpper tract urothelial carcinoma (UTUC)

Identifiers

PMID27342991
PMCPMC6777567
OpenAlexW2466044573

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.